A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 Mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects with Chronic Rhinosinusitis Without Nasal Polyps
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Acronyms Re-Open 3
- Sponsors OptiNose
Most Recent Events
- 05 Mar 2025 New trial record